查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1715854

代謝體學市場（按成分、適應症、應用和最終用戶分類）—2025-2030 年全球預測

Metabolomics Market by Component, Indication, Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計代謝體學市場在 2024 年的價值將達到 30.5 億美元，在 2025 年將達到 33.9 億美元，複合年成長率為 11.38%，到 2030 年將達到 58.3 億美元。

主要市場統計數據
基準年2024年 30.5億美元
預計2025年 33.9億美元
預測年份 2030 58.3億美元
複合年成長率（%） 11.38%

代謝體學是一門快速發展的學科，它徹底改變了我們理解生物過程和疾病機制的方式。在當今競爭激烈、科學研究日趨激烈的環境下，受分析技術進步、大量「體學」數據湧入以及個人化醫療日益受到重視的推動，該領域正在經歷前所未有的成長。該報告提供了詳細的分析，融合了市場動態、技術突破和創新方法，為相關人員提供了對當前趨勢和未來前景的深入了解。

該學科圍繞著生物系統內代謝物的大規模研究，是藥物發現、疾病診斷和環境安全評估等多個領域研究的基石。研究人員和決策者現在認知到，彌合傳統生化檢測與現代數據豐富的環境之間的差距可以帶來推動創新的改變遊戲規則的見解。在探索這一廣闊領域時，讀者將清楚地了解為成功設定新基準並為次世代應用程式鋪平道路的科學進步和市場驅動力。

在強勁需求和成功融入學術、臨床和工業框架的推動下，該領域正在重塑範式。該報告不僅概述了歷史發展和當前市場情景，還概述了可能對研究成果和商業策略產生重大影響的未來發展軌跡。透過密切關注不斷發展的趨勢，您可以了解代謝體學如何彌合理論研究與實際應用之間的差距，成為追求創新和卓越的行業的重要資源。

改變代謝代謝體學格局的變革

代謝體學的發展經歷了變革性的變化，正以前所未有的速度重塑競爭格局。一個關鍵的變化是最尖端科技和先進分析平台的快速整合，從而實現高通量和靈敏的代謝物檢測。這種演變主要由檢測工具的創新所推動，例如質譜、核磁共振光譜和表面質譜，這些工具正變得越來越複雜並融入尖端的工作流程中。

隨著傳統調查方法被更強大的技術主導方法所取代，行業專家正在觀察市場動態的重大轉變。不斷變化的法規環境、對遺傳基礎的更好理解以及公共和私營部門之間的合作努力共同推動了該領域的發展。這些發展正在鼓勵採用更靈活、以數據為中心的方法，不僅可以提高診斷的準確性，還可以加速藥物舉措。

隨著新平台和軟體創新的出現，生物資訊學工具和服務處於促進數據分析和解釋的前沿。資料庫和服務的不斷改進使得準確解釋曾經被認為幾乎不可能的複雜生化資料成為可能。透過利用這些趨勢，行業領導者不僅可以更好地利用科學突破，還可以將技術創新轉化為商業性機會。

此外，隨著個人化醫療的經濟和社會影響不斷擴大，對研究的持續投資和由此產生的技術進步使代謝體學成為更廣泛的醫療保健轉型的重要支柱。市場格局的這種動態變化使得相關人員必須投資於持續學習並採用整合技術和臨床見解的方法。

揭示代謝體學中的關鍵細分見解

代謝體學的細分格局複雜而微妙，提供了超越傳統界限的市場動態的多方面視角。首先，根據組件進行細分時，市場被分為生物資訊學工具和服務以及代謝體學儀器進行分析。生物資訊學領域進一步分為專用服務和廣泛的工具和資料庫，而代謝組學分析儀器類別則更深入，區分檢測和分離工具。檢測工具對於準確的定量和定性分析至關重要，分為質譜、核磁共振波譜和表面質譜等技術。同樣重要的是分離樣品所必需的分離工具，其中包括毛細管電泳、氣相層析法、高效液相層析和超高效液相層析等多種策略。

另一層細分是適應症方面，我們研究心血管、代謝、神經學、腫瘤學等各種疾病的市場。這種分類不僅突顯了應用的多樣性，而且強調了代謝組學分析策略在解決多器官疾病方面的相關性。每種適應症都將成為治療和診斷創新的基準，確保代謝體學的應用得到改進並發揮最大作用。

細分還可以透過基於應用程式的洞察進行擴展。該領域的研究受到生物標記發現、藥物發現、環境科學、營養基因組學、個人化醫療和毒性測試等關鍵應用的推動。生物標記的發現重點關注癌症和神經系統生物標記，它們為早期檢測和成功的干涉策略提供了重要的催化劑。同樣，藥物發現活動正在加強代謝途徑探索和標靶識別，以支持合理的化合物開發和重新定位策略。在環境科學領域，研究重點是農藥殘留和水質，而營養基因體學研究則關注心血管健康和肥胖問題。此外，個人化醫療利用基因組研究和治療監測來根據患者的個別情況制定干涉措施。這些應用中的每一個都在塑造市場趨勢的同時滿足重要的科學和商業性需求方面發揮著獨特的作用。

最後，透過根據學術研究機構、合約研究組織、製藥公司、生物技術公司等不同群體對市場進行分類，最終用戶細分提供了有價值的見解。這種細分對於理解各相關人員如何利用代謝體學來推動創新並在研究和工業業務中獲得競爭優勢至關重要。綜合起來，這種多層次的細分提供了一幅全面的圖景，展示了不同的元素如何結合在一起，創造一個滿足動態和不斷變化的需求的生態系統。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 提高公眾和政府代謝體學在醫療保健中的重要性的認知
      • 全球範圍內慢性病和文明病的發生率正在增加。
      • 代謝體學組學質譜和核磁共振技術的進展
    • 限制因素
      • 代謝體學研究設備高成本
    • 機會
      • 個人化醫療需求的不斷成長和代謝體學技術的進步
      • 拓展代謝體學在法醫學的應用，獲得更準確、可靠的毒理學結果
    • 任務
      • 代謝體學研究中缺乏訓練有素的專家，資料整合困難
  • 市場區隔分析
    • 組成：毛細管電泳在分離少量複雜混合物中扮演重要角色。
    • 適應症：對個人化醫療日益成長的興趣將推動代謝體學的需求
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章代謝體學市場（依成分）

  • 生物資訊學工具和服務
    • 生物資訊服務
    • 生物資訊工具和資料庫
  • 代謝體學學儀器
    • 發現工具
      • 質譜法
      • 核磁共振波譜
      • 基於表面的質譜法
    • 隔離工具
      • 毛細管電泳
      • 氣相層析法
      • 高效液相層析
      • 超高效液相層析

第7章代謝體學市場（按適應症）

  • 心血管疾病
  • 代謝紊亂
  • 神經系統疾病
  • 腫瘤疾病

第 8 章代謝體學市場（按應用）

  • 生物標記發現
    • 癌症生物標記
    • 神經系統生物標記
  • 藥物研發
    • 代謝途徑
    • 目標識別
  • 環境科學
    • 農藥殘留分析
    • 水質分析
  • 營養基因體學
    • 心血管健康
    • 肥胖調查
  • 個人化醫療
    • 基因組學研究
    • 治療監測
  • 毒性測試

第9章代謝體學市場（按最終用戶）

  • 學術研究所
  • 合約研究組織
  • 製藥和生物技術公司

第 10 章：美洲代謝體學市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

11. 亞太代謝代謝體學市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

12. 歐洲、中東和非洲代謝體學市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Afekta Technologies Ltd.
  • BASF SE
  • Bio-Rad Laboratories, Inc.
  • Biocrates Life Science AG
  • Bruker Corporation
  • Clinical Microbiomics A/S
  • Danaher Corporation
  • DNA Xperts Private Limited
  • General Metabolics
  • Hitachi High-Tech Corporation
  • Human Metabolome Technologies Inc.
  • JASCO Corporation
  • Kore Technology Limited
  • LECO Corporation
  • Merck KGaA
  • Metabolon, Inc.
  • Shimadzu Corporation
  • Techcomp Europe Ltd
  • Thermo Fisher Scientific Inc.
  • Waters Corporation
Product Code: MRR-50124643847C

The Metabolomics Market was valued at USD 3.05 billion in 2024 and is projected to grow to USD 3.39 billion in 2025, with a CAGR of 11.38%, reaching USD 5.83 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 3.05 billion
Estimated Year [2025] USD 3.39 billion
Forecast Year [2030] USD 5.83 billion
CAGR (%) 11.38%

Metabolomics stands out as a rapidly evolving discipline that has transformed the way we comprehend biological processes and disease mechanisms. In today's competitive and scientifically intense environment, the field is witnessing unprecedented growth, driven by advances in analytical technologies, the influx of massive 'omics' data, and an increased prioritization of personalized healthcare approaches. This report provides an in-depth analysis that amalgamates market dynamics, technological breakthroughs, and innovative methodologies to offer stakeholders a robust understanding of the prevailing trends and future outlook.

The discipline, which revolves around the large-scale study of metabolites within biological systems, has become a cornerstone for research in multiple domains, including drug discovery, disease diagnostics, and environmental safety assessments. Researchers and decision-makers now recognize that bridging the gap between traditional biochemical assays and the modern data-rich environment can unlock transformative insights that fuel innovation. As we explore this expansive landscape, readers will gain clarity on both the scientific advancements and market drivers that are setting new benchmarks for success and paving the way for next-generation applications.

Driven by robust demand and successful integration into academic, clinical, and industrial frameworks, the field is reshaping its paradigms. This report lays down not only the historical development and current market scenario but also delineates future trajectories that could significantly impact both research outcomes and commercial strategies. With a keen eye on evolving trends, one can appreciate how metabolic profiling is bridging theoretical research with practical, real-world applications, making metabolomics an indispensable resource for industries seeking to innovate and excel.

Transformative Shifts Reshaping the Metabolomics Landscape

The evolution of metabolomics has witnessed transformative shifts that are reshaping the competitive landscape at an unprecedented pace. One key change is the rapid integration of cutting-edge technologies and advanced analytical platforms that enable high-throughput and highly sensitive metabolite detection. This evolution is driven largely by emerging innovations in detection tools, such as mass spectrometry, nuclear magnetic resonance spectroscopy, and surface-based mass analysis, which are increasingly refined and integrated into state-of-the-art workflows.

Industry experts have observed significant shifts in market dynamics as traditional research methods are replaced by more robust, technology-driven approaches. Changing regulatory milieus, an increased understanding of genetic underpinnings, and collaborative efforts between the public and private sectors have collectively propelled the field. These developments encourage a more agile, data-centric approach that not only enhances diagnostic accuracy but also accelerates drug discovery initiatives.

With the advent of new platforms and software innovations, bioinformatics tools and services are now at the forefront of facilitating data analysis and interpretation. The continuous refinement of databases and services is enabling precise interpretations of complex biochemical data, which was once considered near-impossible. As industry leaders harness these trends, they are poised to not only capitalize on scientific breakthroughs but also convert technological innovations into commercial opportunities.

Furthermore, as the economic and societal implications of personalized medicine continue to grow, ongoing investments in research and the resultant technological advancements position metabolomics as a key pillar in the broader narrative of healthcare transformation. This dynamic reformation in the market landscape is making it imperative for stakeholders to invest in continuous learning and embrace integrated approaches that unite technology with clinical insights.

Unveiling Key Segmentation Insights in Metabolomics

The segmentation landscape in metabolomics is both complex and nuanced, providing a multi-dimensional view into market dynamics that transcend traditional boundaries. Initially, when exploring segmentation based on component, the market is analyzed by dividing it into bioinformatics tools and services along with metabolomic instruments. The bioinformatics domain is further classified into dedicated services and a broad array of tools and databases, while the category of metabolomic instruments is delved into depth by distinguishing between detection tools and separation tools. Detection tools form a pivotal component in achieving precise quantitative and qualitative analyses, being subdivided into technologies such as mass spectrometry, nuclear magnetic resonance spectroscopy, and surface-based mass analysis. Equally important are separation tools that are critical for sample resolution, which in this context, include a range of strategies from capillary electrophoresis, gas chromatography, high-performance liquid chromatography, to ultra performance liquid chromatography.

Another layer of segmentation looks at the indication side, where the market is studied across various disorders including cardiovascular, metabolic, neurological, and oncological conditions. This categorization not only highlights the diversity of applications but also underscores the relevance of metabolomic strategies in addressing multi-systemic disorders. Each indication serves as a benchmark for innovation in therapeutic and diagnostic modalities, ensuring that the application of metabolomics is refined and targeted for maximum impact.

Segmentation also unfolds through application-based insights. In this realm, research is driven by major applications such as biomarker discovery, drug discovery, environmental science, nutrigenomics, personalized medicine, and toxicology testing. For biomarker discovery, an important focus is cast on both cancer and neurological biomarkers which are critical triggers for early detection and successful intervention strategies. Similarly, drug discovery efforts are enhanced by investigations into metabolic pathways and target identification, which support streamlined compound development and repositioning strategies. In the environmental science segment, analyses concentrate on pesticide residue and water quality, while nutrigenomics studies investigate cardiovascular health alongside obesity research. Moreover, personalized medicine leverages genomic studies and therapeutic monitoring to tailor interventions that align with individual patient profiles. Each of these applications plays a distinct role in molding market trends while fulfilling a critical demand in scientific and commercial arenas.

Finally, end-user segmentation provides invaluable insights by categorizing the market based on distinct groups such as academic research institutes, contract research organizations, and pharmaceutical as well as biotechnology companies. This segmentation is crucial in understanding how different stakeholders leverage metabolomics to drive innovation and competitive advantage in both research and industrial operations. Collectively, this multi-layered segmentation offers an exhaustive view of how various elements combine to create an ecosystem that is both dynamic and responsive to evolving needs.

Based on Component, market is studied across Bioinformatics Tools & Services and Metabolomic Instruments. The Bioinformatics Tools & Services is further studied across Bioinformatics Services and Bioinformatics Tools & Databases. The Metabolomic Instruments is further studied across Detection Tools and Separation Tools. The Detection Tools is further studied across Mass Spectrometry, Nuclear Magnetic Resonance Spectroscopy, and Surface-based Mass Analysis. The Separation Tools is further studied across Capillary Electrophoresis, Gas Chromatography, High-Performance Liquid Chromatography, and Ultra Performance Liquid Chromatography.

Based on Indication, market is studied across Cardiovascular Disorders, Metabolic Disorders, Neurological Disorders, and Oncological Disorders.

Based on Application, market is studied across Biomarker Discovery, Drug Discovery, Environmental Science, Nutrigenomics, Personalized Medicine, and Toxicology Testing. The Biomarker Discovery is further studied across Cancer Biomarkers and Neurological Biomarkers. The Drug Discovery is further studied across Metabolic Pathways and Target Identification. The Environmental Science is further studied across Pesticide Residue Analysis and Water Quality Analysis. The Nutrigenomics is further studied across Cardiovascular Health and Obesity Research. The Personalized Medicine is further studied across Genomic Studies and Therapeutic Monitoring.

Based on End-User, market is studied across Academic Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies.

Key Regional Insights Illuminating Market Trends

The global landscape of metabolomics presents a rich tapestry of regional variations that offer both challenges and remarkable opportunities. In the Americas, a robust infrastructure combined with strong financial backing and advancing technological ecosystems makes the region a pioneering hub for both innovation and clinical applications. Research facilities and healthcare institutions in this region are particularly adept at integrating novel metabolomic technologies with clinical workflows, thereby spearheading groundbreaking developments across academic and industrial spheres.

In Europe, Middle East and Africa, a diverse economic architecture underpins the market dynamics. The integration of legacy systems with modern technologies in these regions is resulting in innovative methodological adaptations that cater to both established and emerging healthcare needs. This region is characterized by a unique blend of regulatory support, private investments, and public funding initiatives designed to nurture research excellence and industrial competitiveness. The evolving policies and strategic collaborations between various institutions have gradually cemented this region as a significant player in the global metabolomics domain.

Asia-Pacific is experiencing a rapid surge in research and industrial activities related to metabolomics, fueled by increased investment in biotechnology, an expanding pool of skilled professionals, and a burgeoning consumer market focused on personalized solutions. The accelerated pace of technological adaptation combined with pragmatic government policies has positioned the region as a fertile ground for innovation. These regional trends exemplify how a dynamic interplay between economic resilience and technological advancements can catalyze market growth and foster collaborative synergies across nations.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Company Insights and Market Innovators

Within the competitive sphere of metabolomics, a host of leading companies continue to forge pathways that drive innovation and set industry standards. Esteemed corporations, including Afekta Technologies Ltd. and BASF SE, leverage deep scientific expertise and robust market strategies to catalyze growth in emerging segments. Pioneering roles are also observed for organizations such as Bio-Rad Laboratories, Inc. and Biocrates Life Science AG, which are at the forefront of refining analytical methods and digital data integration.

Industry behemoths like Bruker Corporation, Danaher Corporation, and Hitachi High-Tech Corporation have significantly contributed to advancing the quality and precision of metabolomic instruments. These companies, with their sophisticated technologies and comprehensive service portfolios, have managed to bridge the gap between foundational scientific research and commercial usability. Equally notable are specialized players such as Clinical Microbiomics A/S and DNA Xperts Private Limited, each demonstrating singular competencies in niche segments that drive both innovation and market penetration. The contributions of General Metabolics and Human Metabolome Technologies Inc. cannot be understated as they push the technological envelope further, ensuring that detection and separation methodologies remain at the industry's cutting edge.

Collaborative ventures with firms like JASCO Corporation, Kore Technology Limited, LECO Corporation, and Merck KGaA have resulted in trailblazing product lines that not only enhance laboratory performance but also support data analytics for better decision making. The integration of these technological solutions with a focus on comprehensive customer service is reflected in the strategic moves by Metabolon, Inc., Shimadzu Corporation, Techcomp Europe Ltd, Thermo Fisher Scientific Inc., and Waters Corporation. Their continuous innovation cycles and solid market strategies have collectively shaped an ecosystem where scientific exploration meets market viability in a seamless and synergistic manner.

These companies are setting benchmarks in quality and innovation while fostering competitive collaborations that stimulate market awareness and technological excellence. Their roles are not limited to providing advanced technologies but extend into offering holistic service models that nurture research capabilities and drive the overall evolution of the metabolomics sector.

The report delves into recent significant developments in the Metabolomics Market, highlighting leading vendors and their innovative profiles. These include Afekta Technologies Ltd., BASF SE, Bio-Rad Laboratories, Inc., Biocrates Life Science AG, Bruker Corporation, Clinical Microbiomics A/S, Danaher Corporation, DNA Xperts Private Limited, General Metabolics, Hitachi High-Tech Corporation, Human Metabolome Technologies Inc., JASCO Corporation, Kore Technology Limited, LECO Corporation, Merck KGaA, Metabolon, Inc., Shimadzu Corporation, Techcomp Europe Ltd, Thermo Fisher Scientific Inc., and Waters Corporation. Actionable Recommendations for Industry Leaders

Decision-makers and industry leaders are encouraged to adopt a forward-thinking strategy to leverage the inherent opportunities within the metabolomics market. Foremost, it is imperative to invest in state-of-the-art technologies and research and development initiatives that continuously enhance detection precision and analytical reliability. Building cross-functional collaborations between academic, clinical, and industry partners can not only foster innovation but also streamline the translation of metabolomic insights into tangible, marketable applications.

In addition, aligning corporate strategies with evolving regulatory standards and fostering a culture of continuous improvement is essential. Leaders should prioritize the integration of robust quality management systems and leverage digital transformation across their operational models. This not only enhances process efficiency but also improves the overall quality of research outputs and commercial products.

It is also advisable to diversify portfolio investments by exploring various segmentation engines such as component-based differentiation, indication for targeted therapies, and application-specific research. This diversified approach mitigates risk while tapping into niche markets that are often characterized by higher growth potential. Industry leaders should also consider how emerging trends in personalized medicine, nanotechnology, and artificial intelligence can be assimilated into existing frameworks, thus driving competitive advantage.

Furthermore, companies are encouraged to cultivate an ecosystem that prioritizes skill development and talent acquisition. Strategic hires and continued professional development programs ensure that the workforce remains adept at handling the latest technological innovations and adept at innovators' challenges. Strengthening research capabilities through targeted funding and appropriate resource allocation not only bolsters overall market positioning but also enhances the practical applicability of metabolomic insights.

Finally, maintaining agility in formulation and execution of commercial strategies is key. Organizations must continuously monitor global trends and market responses, ensuring that they remain adaptive to changes in consumer behavior and technological evolution. Moving beyond conventional approaches and embracing next-generation insights will undoubtedly reinforce market leadership and pave the way for sustained growth in the dynamically evolving field of metabolomics.

Conclusion: Synthesis of Metabolomics Market Trends

In summarizing the expansive landscape of metabolomics, several pivotal themes emerge that underline the evolution and future trajectory of this dynamic field. The integration of advanced analytical instruments and sophisticated bioinformatics tools has not only redefined research methodologies but also enabled a more nuanced understanding of complex metabolic processes. This transformative shift is driving significant investments in both technology and human capital, thereby laying a strong foundation for the future growth of the market.

The detailed segmentation analysis underscores how a multi-faceted approach - involving components, indications, applications, and end-user insights - interweaves to create a resilient and responsive market ecosystem. Each segmentation parameter reveals layers of opportunity, whether it is harnessing the power of mass spectrometry and nuclear magnetic resonance technologies or addressing critical healthcare challenges such as cardiovascular and metabolic disorders.

Regional factors also continue to play a critical role in shaping market dynamics. The Americas, with its advanced infrastructure; Europe, Middle East and Africa, with its blend of tradition and innovation; and Asia-Pacific's rapid ascent in technology adoption together paint a picture of a truly global evolution in the domain of metabolomics. Key players in the market, ranging from industry giants to specialized firms, are collectively propelling this revolution through innovative solutions and strategic operational excellence.

This synthesis of market trends and insights emphasizes that metabolomics is not just a scientific field but a transformative conduit that bridges research and real-world clinical applications. As industries evolve and new challenges emerge, the ability to adapt, innovate, and integrate will determine long-term success in capitalizing on this robust market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing public and government awareness regarding the importance of metabolomics in healthcare
      • 5.1.1.2. Rising prevalence of chronic and lifestyle-related diseases across the globe
      • 5.1.1.3. Advancements in mass spectrometry and nuclear magnetic resonance technologies for metabolomics
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with metabolomics research instruments
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing demand for personalized medicine combined with advancements in metabolomics technologies
      • 5.1.3.2. Increasing application of metabolomics in forensic science for more accurate and reliable toxicology results
    • 5.1.4. Challenges
      • 5.1.4.1. Limited availability of trained professionals and data integration difficulties in metabolomics research
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Component: Capillary electrophoresis plays a crucial role in resolving small volumes of complex mixtures
    • 5.2.2. Indication: Rising emphasis on personalized medicine accelerates demand for metabolomics
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Metabolomics Market, by Component

  • 6.1. Introduction
  • 6.2. Bioinformatics Tools & Services
    • 6.2.1. Bioinformatics Services
    • 6.2.2. Bioinformatics Tools & Databases
  • 6.3. Metabolomic Instruments
    • 6.3.1. Detection Tools
      • 6.3.1.1. Mass Spectrometry
      • 6.3.1.2. Nuclear Magnetic Resonance Spectroscopy
      • 6.3.1.3. Surface-based Mass Analysis
    • 6.3.2. Separation Tools
      • 6.3.2.1. Capillary Electrophoresis
      • 6.3.2.2. Gas Chromatography
      • 6.3.2.3. High-Performance Liquid Chromatography
      • 6.3.2.4. Ultra Performance Liquid Chromatography

7. Metabolomics Market, by Indication

  • 7.1. Introduction
  • 7.2. Cardiovascular Disorders
  • 7.3. Metabolic Disorders
  • 7.4. Neurological Disorders
  • 7.5. Oncological Disorders

8. Metabolomics Market, by Application

  • 8.1. Introduction
  • 8.2. Biomarker Discovery
    • 8.2.1. Cancer Biomarkers
    • 8.2.2. Neurological Biomarkers
  • 8.3. Drug Discovery
    • 8.3.1. Metabolic Pathways
    • 8.3.2. Target Identification
  • 8.4. Environmental Science
    • 8.4.1. Pesticide Residue Analysis
    • 8.4.2. Water Quality Analysis
  • 8.5. Nutrigenomics
    • 8.5.1. Cardiovascular Health
    • 8.5.2. Obesity Research
  • 8.6. Personalized Medicine
    • 8.6.1. Genomic Studies
    • 8.6.2. Therapeutic Monitoring
  • 8.7. Toxicology Testing

9. Metabolomics Market, by End-User

  • 9.1. Introduction
  • 9.2. Academic Research Institutes
  • 9.3. Contract Research Organizations
  • 9.4. Pharmaceutical & Biotechnology Companies

10. Americas Metabolomics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Metabolomics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Metabolomics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. TNAU partners with start-ups for pioneering metabolomics research
    • 13.3.2. Trinity Biotech announces acquisition of Metabolomics Diagnostics
    • 13.3.3. Metabolon secures USD 60 million credit facility to accelerate growth and innovation in metabolomics
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Afekta Technologies Ltd.
  • 2. BASF SE
  • 3. Bio-Rad Laboratories, Inc.
  • 4. Biocrates Life Science AG
  • 5. Bruker Corporation
  • 6. Clinical Microbiomics A/S
  • 7. Danaher Corporation
  • 8. DNA Xperts Private Limited
  • 9. General Metabolics
  • 10. Hitachi High-Tech Corporation
  • 11. Human Metabolome Technologies Inc.
  • 12. JASCO Corporation
  • 13. Kore Technology Limited
  • 14. LECO Corporation
  • 15. Merck KGaA
  • 16. Metabolon, Inc.
  • 17. Shimadzu Corporation
  • 18. Techcomp Europe Ltd
  • 19. Thermo Fisher Scientific Inc.
  • 20. Waters Corporation

LIST OF FIGURES

  • FIGURE 1. METABOLOMICS MARKET MULTI-CURRENCY
  • FIGURE 2. METABOLOMICS MARKET MULTI-LANGUAGE
  • FIGURE 3. METABOLOMICS MARKET RESEARCH PROCESS
  • FIGURE 4. METABOLOMICS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL METABOLOMICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL METABOLOMICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL METABOLOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL METABOLOMICS MARKET SIZE, BY COMPONENT, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL METABOLOMICS MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL METABOLOMICS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL METABOLOMICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL METABOLOMICS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL METABOLOMICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL METABOLOMICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL METABOLOMICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS METABOLOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS METABOLOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES METABOLOMICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES METABOLOMICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. METABOLOMICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. METABOLOMICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. METABOLOMICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL METABOLOMICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL METABOLOMICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. METABOLOMICS MARKET DYNAMICS
  • TABLE 7. GLOBAL METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & DATABASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL METABOLOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL METABOLOMICS MARKET SIZE, BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL METABOLOMICS MARKET SIZE, BY SURFACE-BASED MASS ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL METABOLOMICS MARKET SIZE, BY CAPILLARY ELECTROPHORESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL METABOLOMICS MARKET SIZE, BY GAS CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL METABOLOMICS MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL METABOLOMICS MARKET SIZE, BY ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL METABOLOMICS MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL METABOLOMICS MARKET SIZE, BY CANCER BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC PATHWAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL METABOLOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL METABOLOMICS MARKET SIZE, BY PESTICIDE RESIDUE ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL METABOLOMICS MARKET SIZE, BY WATER QUALITY ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL METABOLOMICS MARKET SIZE, BY OBESITY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL METABOLOMICS MARKET SIZE, BY GENOMIC STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL METABOLOMICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL METABOLOMICS MARKET SIZE, BY TOXICOLOGY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL METABOLOMICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL METABOLOMICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL METABOLOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 81. ARGENTINA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 82. ARGENTINA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 93. BRAZIL METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 94. BRAZIL METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 95. BRAZIL METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 104. CANADA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 105. CANADA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 106. CANADA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 107. CANADA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 108. CANADA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. MEXICO METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 117. MEXICO METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 118. MEXICO METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 119. MEXICO METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 120. MEXICO METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 121. MEXICO METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. UNITED STATES METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. UNITED STATES METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 130. UNITED STATES METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 131. UNITED STATES METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 132. UNITED STATES METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 133. UNITED STATES METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 134. UNITED STATES METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. UNITED STATES METABOLOMICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 154. AUSTRALIA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. AUSTRALIA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 158. AUSTRALIA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 160. AUSTRALIA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 161. AUSTRALIA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 162. AUSTRALIA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 165. CHINA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 166. CHINA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 167. CHINA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 168. CHINA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. CHINA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. CHINA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 171. CHINA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 172. CHINA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 173. CHINA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 174. CHINA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 175. CHINA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. INDIA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 177. INDIA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 178. INDIA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 179. INDIA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 180. INDIA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 181. INDIA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. INDIA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. INDIA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 184. INDIA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 185. INDIA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 186. INDIA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 187. INDIA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 188. INDIA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. INDONESIA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 190. INDONESIA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 191. INDONESIA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 192. INDONESIA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 193. INDONESIA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 194. INDONESIA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 195. INDONESIA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 196. INDONESIA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 197. INDONESIA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 198. INDONESIA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 199. INDONESIA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 200. INDONESIA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 201. INDONESIA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. JAPAN METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 203. JAPAN METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 204. JAPAN METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 205. JAPAN METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 206. JAPAN METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 207. JAPAN METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 208. JAPAN METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. JAPAN METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 210. JAPAN METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 211. JAPAN METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 212. JAPAN METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 213. JAPAN METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 214. JAPAN METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 215. MALAYSIA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 216. MALAYSIA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 217. MALAYSIA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 218. MALAYSIA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 219. MALAYSIA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 220. MALAYSIA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 221. MALAYSIA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 222. MALAYSIA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 223. MALAYSIA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 224. MALAYSIA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 225. MALAYSIA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 226. MALAYSIA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 227. MALAYSIA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. PHILIPPINES METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 230. PHILIPPINES METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 232. PHILIPPINES METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 234. PHILIPPINES METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 236. PHILIPPINES METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 238. PHILIPPINES METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 239. PHILIPPINES METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 240. PHILIPPINES METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 241. SINGAPORE METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 242. SINGAPORE METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 243. SINGAPORE METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 244. SINGAPORE METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 245. SINGAPORE METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 246. SINGAPORE METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 247. SINGAPORE METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 248. SINGAPORE METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 249. SINGAPORE METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 250. SINGAPORE METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 251. SINGAPORE METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 252. SINGAPORE METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 253. SINGAPORE METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 254. SOUTH KOREA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 256. SOUTH KOREA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 258. SOUTH KOREA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 260. SOUTH KOREA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 262. SOUTH KOREA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 263. SOUTH KOREA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 264. SOUTH KOREA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 265. SOUTH KOREA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 266. SOUTH KOREA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. TAIWAN METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 268. TAIWAN METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 269. TAIWAN METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 270. TAIWAN METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 271. TAIWAN METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 272. TAIWAN METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 273. TAIWAN METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 274. TAIWAN METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 275. TAIWAN METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 276. TAIWAN METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 277. TAIWAN METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 278. TAIWAN METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 279. TAIWAN METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 280. THAILAND METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 281. THAILAND METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 282. THAILAND METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 283. THAILAND METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 284. THAILAND METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 285. THAILAND METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 286. THAILAND METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 287. THAILAND METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 288. THAILAND METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 289. THAILAND METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 290. THAILAND METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 291. THAILAND METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 292. THAILAND METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 293. VIETNAM METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 294. VIETNAM METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 295. VIETNAM METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 296. VIETNAM METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 297. VIETNAM METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 298. VIETNAM METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 299. VIETNAM METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 300. VIETNAM METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 301. VIETNAM METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 302. VIETNAM METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 303. VIETNAM METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 304. VIETNAM METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 305. VIETNAM METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 314. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 315. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 316. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 317. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 318. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 319. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 320. DENMARK METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 321. DENMARK METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 322. DENMARK METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 323. DENMARK METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 324. DENMARK METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 325. DENMARK METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 326. DENMARK METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 327. DENMARK METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 328. DENMARK METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 329. DENMARK METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 330. DENMARK METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 331. DENMARK METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 332. DENMARK METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 333. EGYPT METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 334. EGYPT METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 335. EGYPT METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 336. EGYPT METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 337. EGYPT METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 338. EGYPT METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 339. EGYPT METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 340. EGYPT METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 341. EGYPT METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 342. EGYPT METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 343. EGYPT METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 344. EGYPT METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 345. EGYPT METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 346. FINLAND METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 347. FINLAND METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 348. FINLAND METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 349. FINLAND METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 350. FINLAND METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 351. FINLAND METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 352. FINLAND METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 353. FINLAND METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 354. FINLAND METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MI